Provider Alert! Olumiant Clinical Prior Authorization Revision Effective March 27
Date: April 21, 2023 Attention: All Providers Effective Date: March 27, 2023 Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective March 27, 2023, the Health and Human Services Commission (HHSC) revised the clinical prior authorization approval criteria for Olumiant, a Janus Kinase (JAK) Inhibitor. Olumiant is prescribed for adults with severe alopecia areata and adults with moderate to severely active rheumatoid arthritis. The prior authorization approval criteria revisions were made to match the information in the...
